metabolism

Gene Chips to Detect CYP Variations: A New Step Toward Customized Medical Therapy.

... 2C19, 2D6, 2E1, 3A4) account for over 90% of drug metabolism (but do not appear to account for the selectivity of BiDil). Since a patient can take several concurrent medications metabolized by the same CYP enzyme, it should come as no surprise that CYP-related drug interactions are common. Clinicians are gen...

Generex Biotechnology to Make Presentations At 46th Annual Meeting of the European Society of Pediatric Endocrinology

...d clinical practice of paediatricendocrinology and metabolism throughout the world. Founded in 1962,ESPE has increased in both size and scope, becoming one of thelargest and most leading international scientific communities ofpaediatric endocrinologists. About Generex Generex is engaged in the research and de...

Major New Review Supports the Broader Potential of CeNeS COMT Inhibitor Discovery Programme

...alabsorption, short plasma half-life and extensive metabolism issues.The goal of breaking away from this nitrocatechol series has beenachieved by CeNeS scientists, and a number of discrete chemicalseries without the nitrocatechol group have been identified. TheCOMT inhibitor programme was carefully chosen by Ce...

An Investigational Study Released at ADA Showed that Initial Combination Therapy with Januvia (sitagliptin) and Metformin Led to Improvement in Markers of Beta Cell Function in Patients with Type 2 Diabetes

...sitagliptin is excreted unchanged in theurine with metabolism being a minor pathway of elimination. Following...that the primary enzyme responsible for thelimited metabolism of sitagliptin was CYP3A4, with contribution fromCYP2C8. Excretion Following administration of...

Byetta Treatment for Three and a Half Years Associated with Reductions in Cardiovascular Risk Factors in People with Type 2 Diabetes

...ment activities leverage the company'sexpertise in metabolism to develop potential therapies to treatdiabetes and obesity. Amylin is located in San Diego, Californiawith over 1,600 employees nationwide. For more information aboutAmylin and the company's diabetes products, visit <a target="_blank" href="http...

Late Breaking Data Released at ADA Showed that the Investigational Use of Januvia and Metformin as Initial Combination Therapy Provided Significant Glucose Lowering Efficacy over 54 Weeks in Patients with Type 2 Diabetes

...sitagliptin is excreted unchanged in theurine with metabolism being a minor pathway of elimination. Following...that the primary enzyme responsible for thelimited metabolism of sitagliptin was CYP3A4, with contribution fromCYP2C8. Excretion Following administration of...

Genaera Presents Preclinical Data on Trodusquemine (MSI-1436) for the Treatment of Obesity at the American Diabetes Association 67th Scientific Session

...es associated with obesity such asabnormal glucose metabolism and cholesterol elevation. About Genaera Genaera Corporation is focused on advancing the science andtreatment of metabolic diseases. The Company has significant marketopportunities with a first-in-class molecule, trodusquamine (orMSI-1436), that ha...

Elixir Pharmaceuticals Presents Preclinical Data Highlighting Its Ghrelin Antagonist Program at the American Diabetes Association's Annual Meeting

...d consumption and is believedto play a key role in metabolism and energy storage. A naturallyoccurring hormone p...own to beimplicated in the regulation of aging and metabolism in a varietyof organisms. More information about Elixir is available athttp://www.elixirpharm.com/ ...

Elixir Pharmaceuticals Announces Clinical Data at American Diabetes Association Conference Highlighting Ability of Glufast to Maintain Glycemic Control in Patients with Type 2 Diabetes

...own to beimplicated in the regulation of aging and metabolism in a varietyof organisms. More information about Elixir is available athttp://www.elixirpharm.com/ Contact Elixir Pharmaceuticals William Heiden, 617-995-7000 or Media: Burns McClellan for Elixir Pharmaceuticals Justin Jackson <a target="_blan...

Neurologix Announces Publication of Landmark Gene Therapy Study Demonstrating Safety and Statistically Significant Improvement in Patients With Advanced Parkinson's Disease

...seline in both clinical symptomsand abnormal brain metabolism (as measured by positron emissiontomography, or PE...ignificant improvement (p less than 0.001) inbrain metabolism on the treated side of the brain compared to theuntreated side. No adverse events related to the gen...

Amylin Pharmaceuticals to Present New Data from Broad Diabetes and Obesity Programs at ADA 2007

...ment activities leveragethe company's expertise in metabolism to develop potentialtherapies to treat diabetes and obesity. Amylin is located in SanDiego, California with over 1,700 employees nationwide. For moreinformation about Amylin visit <a target="_blank" href="http://www.amylin.com/">http://www.am...

Genaera to Present Preclinical Data on Trodusquemine for the Treatment of Obesity at the American Diabetes Association 67th Scientific Sessions

...es associated with obesity suchas abnormal glucose metabolism and cholesterol elevation. About Genaera Genaera Corporation is focused on advancing the science andtreatment of metabolic diseases. The Company has significant marketopportunities with a first-in-class molecule, trodusquemine (orMSI-1436), that ha...

Barrier Therapeutics Announces Liarozole Phase 2/3 Study Results in Lamellar Ichthyosis

...ongs to a new class ofdrugs known as retinoic acid metabolism blocking agents, or RAMBAs.Retinoic acid, also kno...vitamin A into thebody, RAMBAs work by slowing the metabolism or degradation of thebody's own retinoic acid. This causes the body to maintain higher,potentially t...

Promising Data on Cognitive Effects of Safinamide in Early Parkinson's Disease

...itions inneurology, with Rebif®, as well as in metabolism and growth,with Saizen®, Serostim® and Zorbtive™. The Companyhas recently entered the psoriasis area with Raptiva®. MerckSerono's research programs are focused on growing these businessesand on establishing new therapeutic areas, in...

New Data Confirms Significant Improvement of Disease Signs and Symptoms in Patients with Rheumatoid Arthritis

...icareas such as autoimmune diseases, inflammation, metabolism andcentral nervous system. In 2006 sales by the PharmaceuticalsDivision totalled 33.3 billion Swiss francs, and the DiagnosticsDivision posted sales of 8.7 billion Swiss francs. Roche employsapproximately 75,000 worldwide and has R&D agreements a...

Metabasis Therapeutics Presents Results of Preclinical Studies for MB07811, Its Novel Product Candidate for the Treatment of Hyperlipidemia, at the Endocrine Society's Annual Meeting

...wellas effects on the thyroid hormone axis, muscle metabolism and boneturnover. Metabasis believes that the combination of a TRbeta-selective receptor agonist and liver-targeting could harnessthe efficacy of the approach by avoiding extra-hepatic activationof TR alpha receptors and TR beta receptors that may le...

Elixir Pharmaceuticals Presents Additional Preclinical Data Demonstrating the Potential of Ghrelin Antagonism to Regulate Metabolism, Body Weight and Glycemic Control

...crease fat, including in theliver, and to regulate metabolism through the inhibition ofghrelin," stated Peter Di...havebeen implicated in the regulation of aging and metabolism in avariety of organisms. More information about Elixir is available athttp://www.elixirpharm.com/ ...

Investigational Cancer Drug Pertuzumab Shows Promising Results in Advanced Breast Cancer When Combined with Herceptin

...icareas such as autoimmune diseases, inflammation, metabolism andcentral nervous system. In 2006 sales by the PharmaceuticalsDivision totalled 33.3 billion Swiss francs, and the DiagnosticsDivision posted sales of 8.7 billion Swiss francs. Roche employsroughly 75,000 worldwide and has R&D agreements and str...

MabThera Significantly Extends Survival And Cures More Patients With Aggressive Lymphoma Than Chemotherapy Alone

...icareas such as autoimmune diseases, inflammation, metabolism andcentral nervous system. In 2006 sales by the PharmaceuticalsDivision totalled 33.3 billion Swiss francs, and the DiagnosticsDivision posted sales of 8.7 billion Swiss francs. Roche employsroughly 75,000 worldwide and has R&D agreements and str...

Blood Levels of Paliperidone Extended-Release Tablets are Not Increased by Common Antidepressant

...inhibitor of theCYP2D6 enzyme, and can inhibit the metabolism of some atypicalantipsychotic drugs. Approximately 50 percent of patients withschizophrenia have at least one other psychiatric or medicalcondition requiring medication, most commonly depression.(2) "Drug interactions frequently occur in patients ...

Innovative Cancer Drug MabThera Again Shown To Improve Survival Rates In Patients With Lymphoma

...ic areas suchas autoimmune diseases, inflammation, metabolism and centralnervous system. In 2006 sales by the Pharmaceuticals Divisiontotalled 33.3 billion Swiss francs, and the Diagnostics Divisionposted sales of 8.7 billion Swiss francs. Roche employs roughly75,000 worldwide and has R&D agreements and str...

Ceregene Presents Interim Phase 1 Clinical Data of CERE-110 for the Treatment of Alzheimer's Disease

...baseline, six and 12 months,and increases in brain metabolism were observed in several corticalregions at six months (p<0.05). Further increases in metabolismwere measured at 12 months (p<0.05), representing a potentialreversal of patterns typically observed in Alzheimer's disease. "Based on the encour...

Samaritan Announces Positive Data in Nonclinical (IND) In-Vitro Studies for Promising Alzheimer's Drug

...ing that SP-233, is unlikely tocause, or alter the metabolism of co-administered drugs, and thuscause, a drug-drug interaction, which could give rise to severeside effects. Dr. Janet Greeson, CEO of Samaritan Pharmaceuticals stated, "Weare extremely excited about the potential of SP-233 to not onlyrestore memo...

MabThera Significantly Increases Survival of Lymphoma Patients Regardless of Chemotherapy Regimen

...ic areas suchas autoimmune diseases, inflammation, metabolism and centralnervous system. In 2006 sales by the Pharmaceuticals Divisiontotalled 33.3 billion Swiss francs, and the Diagnostics Divisionposted sales of 8.7 billion Swiss francs. Roche employs roughly75,000 worldwide and has R&D agreements and str...

Phase III Data on Safinamide in Parkinson’s Disease Presented at American Academy of Neurology 59th Annual Meeting

...itions inneurology, with Rebif®, as well as in metabolism and growth,with Saizen®, Serostim® and Zorbtive™. The Companyhas recently entered the psoriasis area with Raptiva®. MerckSerono's research programs are focused on growing these businessesand on establishing new therapeutic areas, in...

Merck Serono Announces Presentation of Phase III Clinical Data on Safinamide in Parkinson’s Disease at the American Academy of Neurology 59th Annual Meeting

...itions inneurology, with Rebif®, as well as in metabolism and growth,with Saizen®, Serostim® and Zorbtive™. The Companyhas recently entered the psoriasis area with Raptiva®. MerckSerono's research programs are focused on growing these businessesand on establishing new therapeutic areas, in...

New Data Show Xenical Significantly Reduces Cardiovascular Risk and More Than Doubles Weight Loss Achieved in Overweight and Obese People

...ic areas suchas autoimmune diseases, inflammation, metabolism and centralnervous system. In 2006 sales by the Pharmaceuticals Divisiontotalled 33.3 billion Swiss francs, and the Diagnostics Divisionposted sales of 8.7 billion Swiss francs. Roche employs roughly75,000 worldwide and has R&D agreements and str...

EntreMed Presents Multi-Mechanism Results for ENMD-1198 at AACR Annual Meeting

... 2-methoxyestradiol (2ME2), is designed todecrease metabolism while retaining 2ME2's multiple mechanisms ofaction, including inducing apoptosis, disrupting microtubules, andinhibiting HIF-1 alpha. In preclinical studies, ENMD-1198 has beenshown to be an orally active, antimitotic agent that leads toarrest of ce...

New Data Confirm That Use of Levemir Can Limit Weight Gain

...e. Metabolic consequences of weight losson glucose metabolism and insulin action in type 2 diabetes.Diabetes Obes Metab 2000; 2:121–29 6 Wing RR et al. Long-term effects of modest weight loss in typeII diabetic patients. Arch Intern Med 1987; 147:1749–53 7 de Leiva A. What are the benefits of mode...

Arpida Announces Promising Results of "First-In-Man" Studies With AR-709

...radiolabelled ADME study (absorption,distribution, metabolism and excretion), a Phase I bioavailabilitytrial with a solution and one with a capsule formulation. Arpidabelieves that the availability of an oral formulation couldpotentially fulfil an important clinical medical need for thetreatment of serious bact...

Lipitor Provides Unprecedented Cardiovascular Risk Reductions in Diabetes Patients with Metabolic Syndrome and in Stroke Patients

...author of CARDS and professor of endocrinology and metabolism atUniversity College London Hospital. "These results add to the unique and robust body of evidence forLipitor that includes proven reductions in heart attacks andstrokes, impressive average LDL lowering of 39 percent to 60percent, and an establish...

Diobex Announces Successful Completion of Phase 2a Trial Of DIO-902, a Novel Cortisol Synthesis Inhibitor for Type 2 Diabetes

...l effect of DIO-902 andracemic ketoconazole on the metabolism of atorvastatin, therebyreducing the potential for toxicity. DIO-902 has been proven to beboth more effective and safer than the racemic mixture inpreclinical studies. "We are delighted with the preliminary data that we havegenerated to date, and at...

Study Shows Metabolic Strategy of Stressed Cell

...llyfatal stress. CoA plays key roles in the cell's metabolism byparticipating in biochemical reactions in specific areas throughoutthe cell. "The study provides the first detailed look at how the cellshifts genetic gears to respond to a significant change in itsability to carry on its daily metabolic chores," ...

ZIOPHARM Presents ZIO-201 Lymphoma Data at ISH

...variability intreatment effect associated with the metabolism of IFOS andresistance can develop. The Company believes that ZIO-201 couldbetter deliver the clinical benefits of IFOS without the associatedtoxicities and the development of resistance. Data presented at ISH yesterday highlighted that ZIO-201 was 10...

New Data from the US and Japan Support: No Established Causal Link Between Neuropsychiatric Symptoms and Treatment with Tamiflu US Databases Indicate Psychiatric Symptoms Lower in Influenza Patients Taking Tamiflu Versus Those Not Taking Tamiflu

...ic areas suchas autoimmune diseases, inflammation, metabolism and centralnervous system. In 2006 sales by the Pharmaceuticals Divisiontotalled 33.3 billion Swiss francs, and the Diagnostics Divisionposted sales of 8.7 billion Swiss francs. Roche employs roughly75,000 worldwide and has R&D agreements and str...